ARWRArrowhead Pharmaceuticals
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ:ARWR) focuses on developing medicines that treat intractable diseases by silencing the genes that cause them. Utilizing a broad portfolio of RNA interference (RNAi) therapeutics, Arrowhead aims to tackle illnesses that have been challenging to address through conventional methods. Their projects span a range of therapeutic areas, including cardiovascular diseases, liver diseases, and oncology, with the objective of significantly improving patient outcomes through precision genetic intervention. Arrowhead's commitment to innovation and patient care drives its operations as it seeks to advance its pipeline of novel drug candidates through clinical development and towards commercialization.
What is ARWR known for?
Snapshot
Public US
Ownership
1989
Year founded
476
Employees
Pasadena, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Pasadena, US
Products and/or services of Arrowhead Pharmaceuticals
- Hypertriglyceridemia: Arrowhead is developing therapies to reduce abnormally high levels of triglycerides in the blood, a risk factor for cardiovascular disease.
- Dyslipidemia: They are also working on treatments for abnormal levels of fats in the blood, including high cholesterol, which can contribute to heart disease and stroke.
- Cardiovascular Disease: These potential therapies aim to improve cardiovascular health by addressing underlying causes or mitigating risk factors.
- Inflammatory Pulmonary Diseases: Arrowhead is developing RNAi therapeutics to treat chronic inflammatory lung conditions like asthma and COPD.
- Muco-obstructive Lung Diseases: Their research focuses on therapies that could help manage diseases characterized by mucus buildup and airway obstruction, such as chronic obstructive pulmonary disease (COPD).
- Idiopathic Pulmonary Fibrosis: They are also exploring treatments for scarring of the lung tissue leading to progressive breathing difficulties.
Arrowhead Pharmaceuticals executive team
- Dr. Christopher R. Anzalone Ph.D.Chairman, CEO & President
- Mr. Daniel J. ApelChief Financial Officer
- Mr. Patrick O'Brien J.D., PharmDCOO & Secretary
- Dr. James C. Hamilton M.D., MBAChief Medical Officer and Head of R&D
- Dr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & Calando
- Dr. Vincent Anzalone CFAHead of Investor Relations & VP
- Mr. Howard LovyDirector of Communications
- Dr. Bruce D. Given M.D.Chief Medical Scientist
- Dr. Mark SeefeldHead of Toxicology & VP
- Aaron TanHead of Tax